Your session is about to expire
← Back to Search
CAR-T Cell Therapy for B-Cell Leukemia (TRICAR-ALL Trial)
TRICAR-ALL Trial Summary
This trial is testing a new way to fight blood cancer by combining two existing methods. Antibodies and T cells are being joined together to create CAR-T cells, which are then further enhanced with the addition of the 4-1BB protein.
TRICAR-ALL Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTRICAR-ALL Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.TRICAR-ALL Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am over 18 and can make my own health decisions or have a guardian who can.I have stopped all cancer treatments and recovered from their major side effects.I am between 12 and 21 years old and eligible for the TRICAR-ALL T cell infusion.I do not have any cancer other than the one being studied.My leukemia is not responding to treatment and has markers CD19, CD20, or CD22.I have a brain condition that needs treatment.My leukemia has spread to my brain and is considered uncontrollable.I am not currently on treatments like chemotherapy, and meet specific health criteria.I do not have any severe infections, active viral infections, or immune deficiencies.I am willing to be followed up for up to 15 years if I join the study.I have had a bone marrow transplant and am not currently experiencing active GVHD or taking immunosuppressants.I weigh at least 10 kg.
- Group 1: Autologous TRICAR-ALL T-Cells and lymphodepletion chemotherapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can you brief me on the hazards associated with Autologous TriCAR T-cells and lymphodepletion chemotherapy?
"Due to the research's Phase 1 status and limited proof of efficacy, our team at Power has assigned Autologous TriCAR T-cells and lymphodepletion chemotherapy a score of 1 for safety."
Are there still openings for enrolment in this trial?
"As reported by clinicaltrials.gov, the initial posting of this medical trial was on March 1st 2022 and its last update occured November 3rd 2021. Consequently, it is not currently recruiting participants; however, there are 1418 other trials that remain open to applicants."
Share this study with friends
Copy Link
Messenger